HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Unknown Primary Neoplasms

Subscribe to New Research on Unknown Primary Neoplasms

Metastases in which the tissue of origin is unknown.

Also Known As:

Neoplasms, Unknown Primary; Unknown Primary Neoplasm Metastasis; Neoplasm, Occult Primary; Neoplasm, Unknown Primary; Occult Primary Neoplasm; Primary Neoplasm, Occult; Primary Neoplasm, Unknown; Primary Neoplasms, Occult; Primary Neoplasms, Unknown; Primary Tumor, Unknown; Primary Tumors, Unknown; Tumor, Unknown Primary; Tumors, Unknown Primary; Unknown Primary Neoplasm; Unknown Primary Tumor; Neoplasm Metastasis, Unknown Primary; Neoplasms, Occult Primary; Occult Primary Neoplasms; Unknown Primary Tumors

Networked: 44 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Melanoma (Melanoma, Malignant)
2.	Neoplasms (Cancer)
3.	Carcinoma (Carcinomatosis)
4.	Neoplasm Metastasis (Metastasis)
5.	Adenocarcinoma

Experts

1.	Wang, Shen-Qing: 2 articles (12/2008 - 01/2007)
2.	Li, Ling-Fa: 2 articles (12/2008 - 01/2007)
3.	Wu, Qiu-Liang: 2 articles (12/2008 - 01/2007)
4.	Fan, Jun: 2 articles (12/2008 - 01/2007)
5.	Zhou, Shui-Hong: 2 articles (12/2008 - 01/2007)
6.	Hicks, Rodney J: 2 articles (05/2005 - 02/2003)
7.	Rischin, Danny: 2 articles (05/2005 - 02/2003)
8.	Togashi, Kaori: 1 article (07/2015)
9.	Temma, Takashi: 1 article (07/2015)
10.	Sano, Kohei: 1 article (07/2015)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Unknown Primary Neoplasms:

1.	Etoposide (VP 16)FDA LinkGeneric 01/01/1996 - "We investigated the pharmacokinetics of etoposide given to a patient suffering from multifocal liver metastases from an unknown primary tumor. " 01/01/2005 - "The aim of this study was to evaluate patient and tumor characteristics in 102 patients with unknown primary tumors (UPT) prospectively treated with a combination of carboplatin, doxorubicin, and etoposide, to identify clinical variables predictive of response and survival. " 06/01/1997 - "The combination of paclitaxel, carboplatin, and extended-schedule etoposide is highly active and well tolerated in patients with carcinoma of unknown primary tumor site. " 06/01/1997 - "Fifty-five patients with carcinoma of unknown primary tumor site were treated with the following regimen, administered every 21 days: paclitaxel 200 mg/m2 by 1-hour intravenous (I.V.) infusion on day 1, carboplatin at an estimated area under the concentration-time curve (AUC) of 6.0 on day 1, and etoposide 50 mg alternated with 100 mg orally on days 1 through 10. " 06/01/1997 - "To evaluate the efficacy and toxicity of a novel chemotherapy combination that includes paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of patients with carcinoma of unknown primary tumor site. "
2.	Carboplatin (JM8)FDA LinkGeneric 01/01/2005 - "The aim of this study was to evaluate patient and tumor characteristics in 102 patients with unknown primary tumors (UPT) prospectively treated with a combination of carboplatin, doxorubicin, and etoposide, to identify clinical variables predictive of response and survival. " 06/01/1997 - "The combination of paclitaxel, carboplatin, and extended-schedule etoposide is highly active and well tolerated in patients with carcinoma of unknown primary tumor site. " 06/01/1997 - "Fifty-five patients with carcinoma of unknown primary tumor site were treated with the following regimen, administered every 21 days: paclitaxel 200 mg/m2 by 1-hour intravenous (I.V.) infusion on day 1, carboplatin at an estimated area under the concentration-time curve (AUC) of 6.0 on day 1, and etoposide 50 mg alternated with 100 mg orally on days 1 through 10. " 06/01/1997 - "To evaluate the efficacy and toxicity of a novel chemotherapy combination that includes paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of patients with carcinoma of unknown primary tumor site. "
3.	Doxorubicin (Adriamycin)FDA LinkGeneric 01/01/2005 - "The aim of this study was to evaluate patient and tumor characteristics in 102 patients with unknown primary tumors (UPT) prospectively treated with a combination of carboplatin, doxorubicin, and etoposide, to identify clinical variables predictive of response and survival. "
4.	AntigensIBA 01/01/1987 - "In spite of the negative evaluation for prostatic carcinoma, immunohistochemical studies using immunoperoxidase stains for prostatic-specific antigen demonstrated that the lacrimal sac tumor was metastatic carcinoma from an occult primary neoplasm in the prostate gland. "
5.	Fluorouracil (Carac)FDA LinkGeneric 10/01/1988 - "Leucovorin and 5-fluorouracil as a treatment for disseminated cancer of the pancreas and unknown primary tumors." 12/15/1981 - "Sixteen patients with metastatic disease to the liver (12 colorectal and four unknown primary tumors) were treated in a pilot study of hepatic irradiation (2500-3000 rads in 10-12 fractions) delivered concomitantly with continuous short-term intraarterial infusion of 5-fluorouracil (1 g/d) or FUDR (0.5 mg/kg/d) via a percutaneously placed hepatic artery catheter. " 08/01/1993 - "Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. "
6.	FluorineIBA 03/01/2015 - "To assess diagnostic accuracy of fluorine 18 ((18)F) fluorodeoxyglucose (FDG) combined positron emission tomography (PET) and computed tomography (CT) in the detection of occult primary tumors and determination of optimal care in patients with cervical metastasis of an unknown primary tumor (CUP) compared with contrast material-enhanced CT alone or combined contrast-enhanced CT and magnetic resonance (MR) imaging (CT/MR imaging). " 08/28/2007 - "[The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors]." 02/01/2003 - "The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography (PET) in the detection of unknown primary tumor in patients seen with malignant cervical lymphadenopathy thought to arise from a head and neck primary differs in the published reports to date. " 02/01/2003 - "The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor."
7.	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 05/01/1999 - "[Evaluation of 18F-FDG positron emission tomography (PET) in the detection of unknown primary tumors]." 08/01/2003 - "Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors."
8.	Paclitaxel (Taxol)FDA LinkGeneric 01/01/2013 - "Class III β-tubulin overexpression has been linked to resistance to paclitaxel and correlated with poor survival in ovarian, breast, gastric, non-small-cell lung cancer and unknown primary tumors. " 06/01/1997 - "The combination of paclitaxel, carboplatin, and extended-schedule etoposide is highly active and well tolerated in patients with carcinoma of unknown primary tumor site. " 06/01/1997 - "Fifty-five patients with carcinoma of unknown primary tumor site were treated with the following regimen, administered every 21 days: paclitaxel 200 mg/m2 by 1-hour intravenous (I.V.) infusion on day 1, carboplatin at an estimated area under the concentration-time curve (AUC) of 6.0 on day 1, and etoposide 50 mg alternated with 100 mg orally on days 1 through 10. " 06/01/1997 - "To evaluate the efficacy and toxicity of a novel chemotherapy combination that includes paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of patients with carcinoma of unknown primary tumor site. "
9.	Biological Markers (Surrogate Marker)IBA 06/01/1993 - "Use of biological markers in the diagnosis of cancers of unknown primary tumor." 12/25/2010 - "Although TTF-1 had a higher sensitivity, napsin-A was useful as a surrogate marker when encountering a poorly differentiated lung adenocarcinoma or an unknown primary tumor, particularly in cytologic specimens and difficult cases. "
10.	SiliconesIBA 07/01/2000 - "The indications for MRI of the breast is far established may be defined as follows: 1) patients with silicone implants with or without mastectomy; 2) patients whose breast are difficult to evaluate by combined mammography and ultrasonography, who have: a) had breast conservation therapy, b) axillary lymph-node metastasis from an unknown primary tumor; c) postoperative scarring; d) proven carcinoma of one breast, MRI being performed to exclude multifocality. " 01/01/1998 - "Presently accepted indications for MRI of the breast are: patients with silicone implants after mastectomy or augmentation mammoplasty (detection of recurrence/prosthesis rupture/silicon leakage); patients whose breasts are difficult to evaluate by combined mammography and sonography, who have had breast conservation therapy (local recurrence), or who have proven carcinoma in one breast (multifocality/-centricity or contralateral breast carcinoma) or proven axillary lymph node metastases from an unknown primary tumor, especially when these are hormone receptor positive; patients with extensive postoperative scarring. "

Therapies and Procedures

1.	Lymph Node Excision (Lymph Node Dissection) 02/01/2013 - "Sequential mediastinal lymphadenectomy of an unknown primary tumor." 09/01/2014 - "Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease." 01/01/1989 - "Unknown primary tumors arising in the cervical area are frequently squamous cell carcinomas corresponding to occult primary tumors of the upper aerodigestive mucosae and are efficiently treated by cervicofacial radiotherapy or lymph node dissection. "
2.	Radiotherapy 12/01/1986 - "Between 1968 and 1980, radiotherapy was part of the treatment of 120 patients with cervical nodes from an unknown primary tumor. " 09/01/2006 - "A prospective clinical analysis was carried out to assess the diagnostic and therapeutic impact of fluorodeoxyglucose positron emission tomography (FDG-PET) on planning radiotherapy in patients with advanced head and neck cancer in AJCC Stages III/IV. From July 1999 to May 2004 FDG-PET was performed in 49 patients prior to radiotherapy for exclusion of systemic disease, synchronous second or unknown primary tumors. " 10/01/1983 - "These results indicate that radiotherapy of brain metastases gives good palliation even for patients with unknown primary tumor." 03/01/2013 - "Induction chemotherapy followed by extended-field radiotherapy showed good activity and manageable toxicity in patients with cervical metastases from unknown primary tumors." 03/01/2013 - "This retrospective analysis aimed to evaluate toxicity and activity of a sequential chemoradiation regimen consisting of induction chemotherapy followed by extended-field radiotherapy in patients with cervical metastases from unknown primary tumors. "
3.	Drug Therapy (Chemotherapy) 04/15/1983 - "Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver." 11/01/2011 - "Reversible neuropathy after chemotherapy for metastatic adenocarcinoma from an unknown primary tumor to the sural nerve." 06/01/1993 - "Empirical chemotherapy for adenocarcinoma of unknown primary tumor site." 03/01/2013 - "Induction chemotherapy followed by extended-field radiotherapy showed good activity and manageable toxicity in patients with cervical metastases from unknown primary tumors." 03/01/2013 - "This retrospective analysis aimed to evaluate toxicity and activity of a sequential chemoradiation regimen consisting of induction chemotherapy followed by extended-field radiotherapy in patients with cervical metastases from unknown primary tumors. "
4.	Mastectomy (Mammectomy) 07/01/2000 - "The indications for MRI of the breast is far established may be defined as follows: 1) patients with silicone implants with or without mastectomy; 2) patients whose breast are difficult to evaluate by combined mammography and ultrasonography, who have: a) had breast conservation therapy, b) axillary lymph-node metastasis from an unknown primary tumor; c) postoperative scarring; d) proven carcinoma of one breast, MRI being performed to exclude multifocality. " 01/01/1998 - "Presently accepted indications for MRI of the breast are: patients with silicone implants after mastectomy or augmentation mammoplasty (detection of recurrence/prosthesis rupture/silicon leakage); patients whose breasts are difficult to evaluate by combined mammography and sonography, who have had breast conservation therapy (local recurrence), or who have proven carcinoma in one breast (multifocality/-centricity or contralateral breast carcinoma) or proven axillary lymph node metastases from an unknown primary tumor, especially when these are hormone receptor positive; patients with extensive postoperative scarring. "
5.	Aftercare (After-Treatment) 01/09/2007 - "(18)F-FDG coincidence imaging and registration with integrated CT can be as a prospective tool that can judge the malignancy or benignancy of head and neck tumor, and stage and classify the tumor, and distinguish recurrence or necrosis of tumor after treatment by surgery or radiotherapy, and detect unknown primary tumor. " 12/01/2008 - "(18)F-FDG SPECT-CT can be as a prospective tool that can judge the malignancy or benignity of head and neck tumor, stage and classify the tumor, distinguish recurrence or necrosis or fibrosis of the tumor after treatment by surgery or radiotherapy, and detect unknown primary tumor. "